Bectumomab

Drug Profile

Bectumomab

Alternative Names: Anti-CD22 monoclonal antibody LL2 Tc 99m; ImmuRAID LL2 Tc 99m; LymphoScan

Latest Information Update: 24 Jun 2010

Price : $50

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 18 Sep 2003 Suspended - Phase-III for Non-Hodgkin's lymphoma (diagnosis) in USA (IV)
  • 18 Sep 2003 Suspended - Phase-III for Non-Hodgkin's lymphoma (diagnosis) in European Union (IV)
  • 11 Sep 2001 The US FDA has designated orphan drug status to Bectumomab for lymphoma diagnosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top